30. Allanore Y, Distler O. Advances in cohort enrichment shape future of trial design. Nat Rev Rheumatol 2015;11:72–4.

31. Milette K, Hudson M, Körner A, Baron M, Thombs BD. Canadian Scleroderma Research Group. Sleep disturbances in systemic sclerosis: evidence for the role of gastrointestinal symptoms, pain and pruritus. Rheumatology (Oxford) 2013;52:1715–20.

32. Bodukam V, Hays RD, Maranian P, Furst DE, Seibold JR, Impens A, et al. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Rheumatology (Oxford) 2011;50:330–4.

33. Frech TM, Mar D. Gastrointestinal and hepatic disease in systemic sclerosis. Rheum Dis Clin North Am 2018;44:15–28.

34. Valenzuela A, Song P, Chung L. Calcinosis in scleroderma. Curr Opin Rheumatol 2018;30:554–561.

35. Willems LM, Vrieskolk JE, Schouffoer AA, Poole JL, Stamm TA, Boström C, et al. Effectiveness of nonpharmacologic interventions in systemic sclerosis: a systematic review. Arthritis Care Res (Hoboken) 2015;67:1426–39.

36. Khanna D, Seibold J, Goldin J, Tashkin DP, Furst DE, Wells A. Interstitial lung disease points to consider for clinical trials in systemic sclerosis. Rheumatology (Oxford) 2017;56 Suppl:v27–32.

Erratum

An error was detected in the article by Power et al in the September 2019 issue of Arthritis Care & Research (pages 1178–1185). In the Methods of the abstract on page 1178, the sentence listing the sample sizes should have read “Participants were pre-surgical patients with end-stage knee (n = 539), hip (n = 436), and spine (n = 151) OA.”

We regret the error.